Kristiaan Lenos

Kristiaan Lenos

Auto-generated profile, based on publicly available information

Kristiaan Lenos

Laboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC and University of Amsterdam, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
KLKristiaan J. Lenos
Kristiaan J. Lenos
SBSander Bach
Sander Bach
LMLeandro Ferreira Moreno
Leandro Ferreira Moreno
SHSanne Ten Hoorn
Sanne Ten Hoorn
NSNina R. Sluiter
Nina R. Sluiter
LVLouis Vermeulen
Louis Vermeulen
A significant proportion of colorectal cancer (CRC) patients develop peritoneal metastases (PM) in the course of their disease. PMs are associated with a poor quality of life, significant morbidity and dismal disease outcome. To improve care for this patient group, a better understanding of the molecular characteristics of CRC-PM is required. Here we present a comprehensive molecular characterization of a cohort of 52 patients. This reveals that CRC-PM represent a distinct CRC molecular subtype, CMS4, but can be further divided in three separate categories, each presenting with unique features. We uncover that the CMS4-associated structural protein Moesin plays a key role in peritoneal dissemination. Finally, we define specific evolutionary features of CRC-PM which indicate that polyclonal metastatic seeding underlies these lesions. Together our results suggest that CRC-PM should be perceived as a distinct disease entity.

27 May 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
EDErik van Dijk
Erik van Dijk
TBTom van Den Bosch
Tom van Den Bosch
KLKristiaan J. Lenos
Kristiaan J. Lenos
KMKhalid El Makrini
Khalid El Makrini
LNLisanne E. Nijman
Lisanne E. Nijman
DMD.M. (Daniël) Miedema
D.M. (Daniël) Miedema
Survival rates of cancer patients vary widely within and between malignancies. While genetic aberrations are at the root of all cancers, individual genomic features cannot explain these distinct disease outcomes. In contrast, intra-tumour heterogeneity (ITH) has the potential to elucidate pan-cancer survival rates and the biology that drives cancer prognosis. Unfortunately, a comprehensive and effective framework to measure ITH across cancers is missing. Here, we introduce a scalable measure of chromosomal copy number heterogeneity (CNH) that predicts patient survival across cancers. We show that the level of ITH can be derived from a single-sample copy number profile. Using gene-expression data and live cell imaging we demonstrate that ongoing chromosomal instability underlies the observed heterogeneity. Analysing 11,534 primary cancer samples from 37 different malignancies, we find that copy number heterogeneity can be accurately deduced and predicts cancer survival across tissues of origin and stages of disease. Our results provide a unifying molecular explanation for the different survival rates observed between cancer types.

9 November 2023 in EMBO Molecular Medicine
Verified
Journal Article
Open access
YPYmke van der Pol
Ymke van der Pol
NTNormastuti Adhini Tantyo
Normastuti Adhini Tantyo
NENils Evander
Nils Evander
AHAnouk E Hentschel
Anouk E Hentschel
BWBirgit Mm Wever
Birgit Mm Wever
FMFlorent Mouliere
Florent Mouliere
Cell‐free DNA (cfDNA) can be isolated and sequenced from blood and/or urine of cancer patients. Conventional short‐read sequencing lacks deployability and speed and can be biased for short cfDNA fragments. Here, we demonstrate that with Oxford Nanopore Technologies (ONT) sequencing we can achieve delivery of genomic and fragmentomic data from liquid biopsies. Copy number aberrations and cfDNA fragmentation patterns can be determined in less than 24 h from sample collection. The tumor‐derived cfDNA fraction calculated from plasma of lung cancer patients and urine of bladder cancer patients was highly correlated ( R = 0.98) with the tumor fraction calculated from short‐read sequencing of the same samples. cfDNA size profile, fragmentation patterns, fragment‐end composition, and nucleosome profiling near transcription start sites in plasma and urine exhibited the typical cfDNA features. Additionally, a high proportion of long tumor‐derived cfDNA fragments (> 300 bp) are recovered in plasma and urine using ONT sequencing. ONT sequencing is a cost‐effective, fast, and deployable approach for obtaining genomic and fragmentomic results from liquid biopsies, allowing the analysis of previously understudied cfDNA populations.

2 July 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
KLKristiaan Lenos
Kristiaan Lenos
Jeroen A.C.M. GoosJeroen A.C.M. Goos
Jeroen A.C.M. Goos
IVIlona M. Vuist
Ilona M. Vuist
SUSjoerd H. Den Uil
Sjoerd H. Den Uil
PDPien M. Delis-Van Diemen
Pien M. Delis-Van Diemen
Sandra J. Van VlietSandra J. Van Vliet
Sandra J. Van Vliet
MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients

17 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
JSJ. Saris
J. Saris
AYAndrew Li Yim
Andrew Li Yim
SBS. Bootsma
S. Bootsma
KLK. J. Lenos
K. J. Lenos
RFR. Franco Fernandez
R. Franco Fernandez
JGJoep Grootjans
Joep Grootjans
Patients with peritoneal metastasized colorectal cancer (PM-CRC) have a dismal prognosis. We hypothesized that an immunosuppressive environment in the peritoneal cavity underlies poor prognosis. We define the composition of the human peritoneal immune system (PerIS) using single-cell technologies in 18 patients with- and without PM-CRC, as well as in matched peritoneal metastases (n = 8). Here we show that the PerIS contains abundant immunosuppressive C1Q+VSIG4+ and SPP1+VSIG4+ peritoneal-resident macrophages (PRMs), as well as monocyte-like cavity macrophages (mono-CMs), which share features with tumor-associated macrophages, even in homeostasis. In PM-CRC, expression of immunosuppressive cytokines IL10 and VEGF increases, while simultaneously expression of antigen-presenting molecules decreases in PRMs. These intratumoral suppressive PRMs originate from the PerIS, and intraperitoneal depletion of PRMs in vivo using anti-CSF1R combined with anti-PD1 significantly reduces tumor burden and improves survival. Thus, PRMs define a metastatic site-specific immunosuppressive niche, and targeting PRMs is a promising treatment strategy for PM-CRC.

1 November 2021 in Cell Stem Cell
Verified
Journal Article
Open access
SLSophie C. Lodestijn
Sophie C. Lodestijn
TBTom van Den Bosch
Tom van Den Bosch
LNLisanne E. Nijman
Lisanne E. Nijman
LMLeandro F. Moreno
Leandro F. Moreno
SSSophie Schlingemann
Sophie Schlingemann
LVLouis Vermeulen
Louis Vermeulen
The tissue dynamics that govern maintenance and regeneration of the pancreas remain largely unknown. In particular, the presence and nature of a cellular hierarchy remains a topic of debate. Previous lineage tracing strategies in the pancreas relied on specific marker genes for clonal labeling, which left other populations untested and failed to account for potential widespread phenotypical plasticity. Here we employed a tracing system that depends on replication-induced clonal marks. We found that, in homeostasis, steady acinar replacement events characterize tissue dynamics, to which all acinar cells have an equal ability to contribute. Similarly, regeneration following pancreatitis was best characterized by an acinar self-replication model because no evidence of a cellular hierarchy was detected. In particular, rapid regeneration in the pancreas was found to be driven by an accelerated rate of acinar fission-like events. These results provide a comprehensive and quantitative model of cell dynamics in the exocrine pancreas.